Alphamab Oncology (HKG:9966)

Alphamab Oncology Revenue

Alphamab Oncology had revenue of 271.24M CNY in the half year ending June 30, 2026, with 56.28% growth. This brings the company's total for the last twelve months to 518.03M, down -34.09% year-over-year. In the year 2025, Alphamab Oncology had annual revenue of 566.24M, down -11.54%. That makes Alphamab Oncology the 24,745th largest company in the world by revenue and 1,473rd in Hong Kong.

• Revenue (ttm): 518.03M CNY
• Revenue Growth: -34.09%
• P/S Ratio: 11.77
• Revenue / Employee: 1.01M CNY
• Employees: 515
• Market Cap: 6.00B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	566.24M	-73.85M	-11.54%
Dec 31, 2024	640.08M	421.31M	192.58%
Dec 31, 2023	218.77M	51.93M	31.12%
Dec 31, 2022	166.85M	20.82M	14.26%
Dec 31, 2021	146.02M	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 24, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 17, 2026

Data Sources Report a data error